-
Uncategorized1 month agoFDA pauses schizophrenia trial after patient death
The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant. Evenamide, developed...
-
Uncategorized1 month ago
XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
-
Uncategorized1 month agoSTAT+: Cigna will exit ACA individual markets next year, adding to tumult for patients
Cigna is pulling out of the Affordable Care Act’s individual marketplaces in 2027 to focus on more promising parts of its business, another exit from what’s...
-
Uncategorized1 month ago
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing...
-
Uncategorized1 month ago
What we heard at a health tech conference in Boston
I just came back from the Digital Healthcare Innovation Summit in Boston earlier this week, where I got a good look into what investors are thinking...
-
Uncategorized1 month ago
BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later...
-
Uncategorized1 month ago
AstraZeneca’s camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca’s proposal of using its oral SERD camizestrant in a novel first-line switch setting in...
-
Uncategorized1 month agoSTAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus, but our spirits remain sunny, nonetheless....
-
Uncategorized1 month ago
CVS’ healthcare delivery chief eyes potential in clinical AI
CVS Health has been testing AI tools that deliver healthcare, though it sees too many barriers to using them more widely for now. CVS’ President of...
-
Uncategorized1 month ago
Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth
Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.
